The Evolving Landscape of Hepatocellular Carcinoma Mortality in the US

Menée aux Etats-Unis à partir de données 2006-2022 du Système national de statistiques de l'état civil, cette étude examine l'évolution des taux de décès par carcinome hépatocellulaire et établit une projection sur la période 2023-2040

Résumé en anglais

Hepatocellular carcinoma (HCC) is the most common primary liver malignant neoplasm, with an increasing incidence and mortality in the US. The study by Qiu et al provides a thorough analysis of the evolving trends in HCC mortality. This study highlights the alarming rise in HCC deaths attributed to alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), with a concurrent decline in mortality from viral hepatitis. Specifically, Qiu et al found that the rates of HCC associated with ALD and MASLD in the US increased rapidly between 2006 and 2022. By 2026, ALD-related HCC is expected to become the leading cause, with MASLD-related HCC projected to be the second-leading cause by 2032. These are important insights into the changing etiologies driving the development of HCC, which highlights the future health care challenges in preventing and treating both these underlying conditions and HCC itself.